LOWELL, Mass., May 22, 2018 /PRNewswire/ -- Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful ...
The MarketWatch News Department was not involved in the creation of this content. -- Peer-reviewed data published in Neurosurgery show that SOLOPASS(R) 2.0 delivers significantly higher accuracy than ...
Approximately one year after the company landed FDA approval for its Ventricular Assist System, the company is boasting significant surge in revenue. In early morning trading on November 7, the ...
With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.
SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the ...
98% of placements using SOLOPASS® 2.0 entered the ventricular system, versus only 10% of freehand placements. 86% of placements using SOLOPASS® 2.0 accurately reached the ipsilateral frontal horn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results